Investment will scale comprehensive, tech-enabled kidney care to reign in treatment costs and improve patient health outcomes
DENVER, CO. — Strive Health, the national leader in value-based kidney care, today announced that the company secured a $140 million Series B round of funding led by CapitalG, Alphabet’s independent growth fund. Redpoint also joins current investors NEA, Town Hall Ventures, Ascension Ventures and Echo Ventures to complete the round. The financing will support the growing demand for Strive’s innovative whole-patient solution for kidney disease populations. This brings Strive’s total funding to $223.5 million.
Strive’s model combines advanced technology with high-touch patient care to slow kidney disease progression, prevent unnecessary and costly hospitalizations, and expand access to optimal renal replacement therapies such as home dialysis and transplants. The growing national spotlight on kidney care and the demand for value-based healthcare solutions has helped Strive more than double its presence in regional markets and grow its employee base by more than 600% in the last year.
The new partnership with CapitalG is expected to amplify Strive’s position as the leader in value-based kidney care through growth capital and unique access to Google’s and Alphabet’s expertise to support product and go-to-market innovation.
“Chronic and end-stage kidney disease patients continue to be underserved by the current healthcare system. Strive has built an industry-leading kidney care solution that has the potential to transform patients’ lives,” said Sumi Das, partner at CapitalG. “After extensively studying the landscape, we determined that Strive’s technology, care delivery model, and team were best-in-class in the rapidly emerging kidney care segment. We are excited to partner with the Strive team to improve patient outcomes and significantly drive down healthcare costs.”
The announcement serves as further validation that Strive’s tech-enabled high-touch care model can reverse the national health crisis caused by kidney disease. Kidney disease affects 37 million adults and is the nation’s ninth leading cause of death. It disproportionately impacts people of color and significantly elevates the risk of developing serious complications from COVID-19. Despite dismal outcomes, only 10% of people with chronic kidney disease (CKD) are aware they have the disease, over half of late-stage CKD patients have not seen a nephrologist, and roughly 60% of people who experience kidney failure do so in an unplanned way.
“Our focus is on providing great patient care. Technology is a critical aspect of doing this well, and our unique partnership with CapitalG will help us profoundly elevate our growth and technology vision by leveraging the insights and expertise of the best and brightest minds at Google and Alphabet,” said Chris Riopelle, CEO of Strive Health. “We are thrilled by how this partnership will take us to the next level and enable compassionate kidney care the way it should be done.”
The company has signed contracts to deliver its innovative solution to leading healthcare payors and providers, including Humana, Blue Cross and Blue Shield of North Carolina, SSM Health, Conviva Care Centers and more. Strive also has partnerships with hundreds of nephrology providers through new Medicare payment models and aggressive growth plans for the coming year.
Each of us has chosen to dedicate our time to something bigger than ourselves. We are resilient, tenacious, and strive for continuous innovation. We have fun. And we always care for others first.
“At Strive, we’re transforming kidney care. While our mission, vision, and values-based culture play critical roles in that transformation, our people (Strivers) make it happen. Strivers are delivering compassionate kidney care and creating an incredible place to work.”
Let’s do better for kidney disease patients and improve our kidney care system together. Contact us now!CONTACT US
In this quick article, we provide anexecutive summary of the ETC model, what nephrologists need to know, anddiscuss implications for the nephrologists and dialysis facilities.Check out the article